602 related articles for article (PubMed ID: 22990314)
21. Influence of axial length and postinjection reflux on sustained intraocular pressure elevation as a result of intravitreal anti-vascular endothelial growth factor therapy.
Hoang QV; Jung JJ; Mrejen S; Freund KB
Retina; 2014 Mar; 34(3):519-24. PubMed ID: 24240557
[TBL] [Abstract][Full Text] [Related]
22. Effect of prophylactic intraocular pressure-lowering medication on intraocular pressure spikes after intravitreal injections.
Frenkel MP; Haji SA; Frenkel RE
Arch Ophthalmol; 2010 Dec; 128(12):1523-7. PubMed ID: 21149773
[TBL] [Abstract][Full Text] [Related]
23. Retreatment with anti-vascular endothelial growth factor therapy based on changes in visual acuity after initial stabilization of neovascular age-related macular degeneration: 3-year follow-up results.
Dunavoelgyi R; Sacu S; Eibenberger K; Palkovits S; Leydolt C; Pruente C; Schmidt-Erfurth U
Retina; 2012 Sep; 32(8):1471-9. PubMed ID: 22414958
[TBL] [Abstract][Full Text] [Related]
24. Intravitreal bevacizumab treatment for exudative age-related macular degeneration with good visual acuity.
Axer-Siegel R; Bor E; Bourla DH; Weinberger D; Mimouni K
Retina; 2012 Oct; 32(9):1811-20. PubMed ID: 22825407
[TBL] [Abstract][Full Text] [Related]
25. Intraocular pressure in patients with neovascular age-related macular degeneration switched to aflibercept injection after previous anti-vascular endothelial growth factor treatments.
Rusu IM; Deobhakta A; Yoon D; Lee M; Slakter JS; Klancnik JM; Thompson D; Freund KB
Retina; 2014 Nov; 34(11):2161-6. PubMed ID: 25072648
[TBL] [Abstract][Full Text] [Related]
26. Ocular hypertension and intraocular pressure asymmetry after intravitreal injection of anti-vascular endothelial growth factor agents.
Pershing S; Bakri SJ; Moshfeghi DM
Ophthalmic Surg Lasers Imaging Retina; 2013; 44(5):460-4. PubMed ID: 24044708
[TBL] [Abstract][Full Text] [Related]
27. Persistent ocular hypertension following intravitreal bevacizumab and ranibizumab injections.
Adelman RA; Zheng Q; Mayer HR
J Ocul Pharmacol Ther; 2010 Feb; 26(1):105-10. PubMed ID: 20187807
[TBL] [Abstract][Full Text] [Related]
28. Intravitreal ranibizumab injection for neovascular age-related macular degeneration in phakic versus pseudophakic eyes.
Baek JS; Cho HJ; Cho SW; Kim CG; Kim JW
Retina; 2013 Mar; 33(3):467-73. PubMed ID: 23400082
[TBL] [Abstract][Full Text] [Related]
29. The Real-World Effect of Intravitreous Anti-Vascular Endothelial Growth Factor Drugs on Intraocular Pressure: An Analysis Using the IRIS Registry.
Atchison EA; Wood KM; Mattox CG; Barry CN; Lum F; MacCumber MW
Ophthalmology; 2018 May; 125(5):676-682. PubMed ID: 29336897
[TBL] [Abstract][Full Text] [Related]
30. Repeated intravitreous ranibizumab injections for diabetic macular edema and the risk of sustained elevation of intraocular pressure or the need for ocular hypotensive treatment.
Bressler SB; Almukhtar T; Bhorade A; Bressler NM; Glassman AR; Huang SS; Jampol LM; Kim JE; Melia M;
JAMA Ophthalmol; 2015 May; 133(5):589-97. PubMed ID: 25719991
[TBL] [Abstract][Full Text] [Related]
31. Intraocular Pressure Changes in Non-Glaucomatous Patients Receiving Intravitreal Anti-Vascular Endothelial Growth Factor Agents.
Kiddee W; Montriwet M
PLoS One; 2015; 10(9):e0137833. PubMed ID: 26360382
[TBL] [Abstract][Full Text] [Related]
32. ASSOCIATION BETWEEN NEEDLE SIZE, POSTINJECTION REFLUX, AND INTRAOCULAR PRESSURE SPIKES AFTER INTRAVITREAL INJECTIONS.
Pang CE; Mrejen S; Hoang QV; Sorenson JA; Freund KB
Retina; 2015 Jul; 35(7):1401-6. PubMed ID: 25650712
[TBL] [Abstract][Full Text] [Related]
33. Effect of intravitreal bevacizumab on retrobulbar blood flow in injected and uninjected fellow eyes of patients with neovascular age-related macular degeneration.
Hosseini H; Lotfi M; Esfahani MH; Nassiri N; Khalili MR; Razeghinejad MR; Nouri-Mahdavi K
Retina; 2012 May; 32(5):967-71. PubMed ID: 22146127
[TBL] [Abstract][Full Text] [Related]
34. Monitoring intraocular pressure changes after intravitreal Ranibizumab injection using rebound tonometry.
Fuest M; Kotliar K; Walter P; Plange N
Ophthalmic Physiol Opt; 2014 Jul; 34(4):438-44. PubMed ID: 24731161
[TBL] [Abstract][Full Text] [Related]
35. Long-term intraocular pressure changes after intravitreal injection of bevacizumab.
Baek SU; Park IW; Suh W
Cutan Ocul Toxicol; 2016 Dec; 35(4):310-4. PubMed ID: 26820610
[TBL] [Abstract][Full Text] [Related]
36. Treatment of neovascular age-related macular degeneration with intravitreal bevacizumab: efficacy of three consecutive monthly injections.
Melamud A; Stinnett S; Fekrat S
Am J Ophthalmol; 2008 Jul; 146(1):91-5. PubMed ID: 18455144
[TBL] [Abstract][Full Text] [Related]
37. Incidence of ocular hypertension after intravitreal injection of anti-VEGF agents in the treatment of neovascular AMD.
Moraru A; Pînzaru G; Moţoc A; Costin D; Brănişteanu D
Rom J Ophthalmol; 2017; 61(3):207-211. PubMed ID: 29450400
[No Abstract] [Full Text] [Related]
38. Efficacy of 12-month treatment of neovascular age-related macular degeneration with intravitreal bevacizumab based on individually determined injection strategies after three consecutive monthly injections.
Mekjavic PJ; Kraut A; Urbancic M; Lenassi E; Hawlina M
Acta Ophthalmol; 2011 Nov; 89(7):647-53. PubMed ID: 19860774
[TBL] [Abstract][Full Text] [Related]
39. Bevacizumab for neovascular age-related macular degeneration in China.
Li X; Hu Y; Sun X; Zhang J; Zhang M;
Ophthalmology; 2012 Oct; 119(10):2087-93. PubMed ID: 22818896
[TBL] [Abstract][Full Text] [Related]
40. Repeated intravitreal anti-vascular endothelial growth factor injections can induce iatrogenic ocular hypertension, especially in patients with open-angle glaucoma.
Agard E; Elchehab H; Ract-Madoux G; Russo A; Lagenaite C; Dot C
Can J Ophthalmol; 2015 Apr; 50(2):127-31. PubMed ID: 25863852
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
